Voriconazole and Caspofungin Acetate in Treating Invasive Fungal Infections in Patients With Weakened Immune Systems

DISEASE CHARACTERISTICS: Diagnosis of probable or definite invasive fungal infection with 1 of the following organisms: Aspergillus species Fusarium species Scedosporium species (Pseudallescheria boydii) Other dematiaceous molds The following diagnosis are not allowed: Zygomycetes (Mucor or Rhizopus species) Chronic aspergillosis Aspergilloma Allergic bronchopulmonary aspergillosis Must be immunocompromised PATIENT CHARACTERISTICS: Age 18 and over Performance status Not specified Life expectancy At least 72 hours Hematopoietic Not specified Hepatic AST < 5 times upper limit of normal (ULN) Bilirubin < 5 times ULN Alkaline phosphatase < 5 times ULN No Child-Pugh class C cirrhosis Renal Creatinine clearance ≥ 50 mL/min Pulmonary No mechanical ventilation Other Not pregnant or nursing Fertile patients must use effective contraception No hypersensitivity to azoles, caspofungin acetate, or their components No history of galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption PRIOR CONCURRENT THERAPY: Biologic therapy Not specified Chemotherapy Not specified Endocrine therapy Not specified Radiotherapy Not specified Surgery Not specified Other More than 14 days since prior therapeutic antifungal therapy of ≥ 1 week duration More than 14 days since prior and no concurrent administration of any of the following medications: Terfenadine Astemizole Cisapride Pimozide Quinidine Sirolimus Rifampin Carbamazepine Long-acting barbiturates Rifabutin Ergot alkaloids (i.e., ergotamine and dihydroergotamine)